A novel process for production of hepatitis A virus in Vero cells grown on microcarriers in bioreactor

被引:12
作者
Sun, Ming-Bo [1 ]
Jiang, Yan-Jun [1 ]
Li, Wei-Dong [1 ]
Li, Ping-Zhong [1 ]
Li, Guo-Liang [1 ]
Jiang, Shu-De [1 ]
Liao, Guo-Yang [1 ]
机构
[1] Chinese Acad Med Sci, Inst Med Biol, Peking Union Med Coll, Kunming 650118, Yunnan Province, Peoples R China
关键词
D O I
10.3748/wjg.v10.i17.2571
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To develop a novel process for production of HAV in Vero cells grown on microcarriers in a bioreactor. METHODS: Vero cells infected with HAV strain W were seeded at an initial density of 1x10(5) cells/mL into a 7-L bioreactor containing Cytodex-I microcarriers. During the stage of cell proliferation, the following conditions were applied: pH 7.2 +/- 0.2, temperature 37 +/- 0.2 degrees C, dissolved oxygen 40% of air saturation and agitation rate 40 r/min. After the stage of virus culture started, the culture conditions were altered to pH 7.2 +/- 0.2, temperature 35 +/- 0.2 degrees C, dissolved oxygen 25% of air saturation, agitation rate 50 r/min and perfusion of fresh medium at a flux of 20 mL/h. During the course of fermentation, cell density, HAV antigen titre, glucose, lactate and ammonia levels were monitored. A control experiment using conventional static culture was conducted in the T150 flask. RESULTS: After a 28-d cultivation, cell density increased to 14.0x10(5) cells/mL in the bioreactor, 5.6x10(9) viable cells and 4 000 mL virus suspension with a titre of 1:64 were harvested. The viral antigen output per cell unit in the bioreactor was 3-fold higher than that in the T150 flask. Meanwhile the metabolic mode of Vero cells did not change after the infection with HAV strain W. CONCLUSION: The process for production of HAV in Vero cells grown on microcarriers in a bioreactor is a novel, efficient and practical way to obtain virus antigen for vaccine purpose. This approach produces more cells and HAV antigen than the conventional static culture. With futher improvement, it is possible to be used for the production of hepatitis A vaccine.
引用
收藏
页码:2571 / 2573
页数:3
相关论文
共 18 条
[1]   The effectiveness and safety of hepatitis A vaccine: a systematic review [J].
Demicheli, V ;
Tiberti, D .
VACCINE, 2003, 21 (19-20) :2242-2245
[2]   Scalable inoculation strategies for microcarrier-based animal cell bioprocesses [J].
Dürrschmid, M ;
Landauer, K ;
Simic, G ;
Blüml, G ;
Doblhoff-Dier, O .
BIOTECHNOLOGY AND BIOENGINEERING, 2003, 83 (06) :681-686
[3]   Vaccination strategies against hepatitis A in southern Europe [J].
Franco, E ;
Vitiello, G .
VACCINE, 2003, 21 (7-8) :696-697
[4]   Detection of the changing substrate requirements of cultured animal cells by stoichiometric growth equations validated by enthalpy balances [J].
Guan, YH ;
Kemp, RB .
JOURNAL OF BIOTECHNOLOGY, 1999, 69 (2-3) :95-114
[5]   Evaluation of the purity of a purified, inactivated hepatitis A vaccine (VAQTA™) [J].
Hennessey, JP ;
Oswald, CB ;
Dong, ZY ;
Lewis, JA ;
Sitrin, RD .
VACCINE, 1999, 17 (22) :2830-2835
[6]  
Huang G, 2000, Zhonghua Liu Xing Bing Xue Za Zhi, V21, P287
[7]   A novel process for the production of a veterinary rabies vaccine in BHK-21 cells grown on microcarriers in a 20-1 bioreactor [J].
Kallel, H ;
Rourou, S ;
Majoul, S ;
Loukil, H .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2003, 61 (5-6) :441-446
[8]   An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA®) in adults:: safety, tolerability, and immunogenicity [J].
Linglöf, T ;
van Hattum, J ;
Kaplan, KM ;
Corrigan, J ;
Duval, I ;
Jensen, E ;
Kuter, B .
VACCINE, 2001, 19 (28-29) :3968-3971
[9]   Combined hepatitis a and B vaccines - A review of their immunogenicity and tolerability [J].
Murdoch, DL ;
Goa, K ;
Figgitt, DP .
DRUGS, 2003, 63 (23) :2625-2649
[10]  
Ren A, 2001, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V15, P357